The fourth evaluated enterprise of escitalopram oxalate tablets was born!

On November 13, Huahai pharmaceutical announced that it had recently received the approval document for drug registration approved and issued by the State Food and drug administration The product was declared according to four categories of new registration classification, and it was deemed to have passed the consistency evaluation after being approved Escitalopram oxalate tablets are mainly used in the treatment of depression Escitalopram oxalate tablets were jointly developed by H lundbecka / s and Allergan In August 2002, the drug was approved for marketing by FDA of the United States In the United States, the manufacturers of escitalopram oxalate tablets mainly include lupin, torrent, Cipla, etc In 2006, the product was approved to be listed in China Domestic manufacturers mainly include Sichuan Kelun Pharmaceutical Co., Ltd and Shandong Jingwei Pharmaceutical Co., Ltd According to the hospital sales database of pharmaceutical intelligence data Enterprise Edition, from 2016 to 2018, after the sales of escitalopram oxalate tablet sample hospital increased in 2017, the sales of escitalopram oxalate tablet decreased by 7.02% year-on-year in 2018, reaching 84.383 million yuan, which is due to the author's guess that there is a great connection with the centralized purchase of drugs Escitalopram oxalate tablet is one of the "4 + 7" volume purchased products In 2018, Kelun pharmaceutical won the bid with a price of 30.94 yuan per box In 2019, it won the bid again at the site of centralized mining and expansion bidding: Kelun pharmaceutical reduced the price by 3%, and the bidding price was 29.89 yuan The price of the original research drug was high, which was a pity to be out of the competition In addition, according to the pharmaceutical intelligence data, up to now, there are four enterprises that have been evaluated for the consistency of escitalopram oxalate tablets, and Huahai pharmaceutical is the fourth one, among which the domestic sample hospital market is mainly occupied by Shandong Jingwei, accounting for 57.4%; it remains to be seen whether the hospital market share of the drug will be divided into a large proportion by the winning of the centralized procurement of Kelun pharmaceutical and the entry of Huahai pharmaceutical Information source: yaozhi.com and Huahai pharmaceutical enterprise announcement data source: yaozhi.com